Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/10/2025

Amiodarone Contraindications and Precautions

Absolute Contraindications

  • Severe sinus node dysfunction is a contraindication for amiodarone use, as stated by the American Academy of Pediatrics 1, 2
  • Second- and third-degree AV block without a functioning pacemaker is a contraindication for amiodarone use, as stated by the American Academy of Family Physicians 3
  • Heart transplant patients should not use amiodarone, according to the American Academy of Pediatrics 2

Relative Contraindications and Precautions

Cardiovascular Conditions

  • The American Academy of Family Physicians recommends caution when using amiodarone in patients with prolonged QT interval, as it can further prolong the QT interval 3, 4
  • Amiodarone should not be used with procainamide or other QT-prolonging medications without expert consultation, as stated by the American Academy of Pediatrics 1

Pulmonary Conditions

  • Inflammatory lung disease may be exacerbated by amiodarone use, according to the American Heart Association 5

Hepatic Conditions

  • The American Academy of Family Physicians recommends caution when using amiodarone in patients with severe hepatic dysfunction, as it can cause hepatotoxicity 4, 6

Thyroid Conditions

  • The American Heart Association and the American Academy of Family Physicians recommend monitoring thyroid function in patients using amiodarone, as it can affect thyroid function 5, 7

Other Considerations

  • The American Heart Association recommends monitoring for peripheral neuropathy, optic neuritis, and abnormal gait/ataxia in patients using amiodarone, as it can cause or worsen these conditions 5

Special Populations and Monitoring Requirements

Patients on Concomitant Medications

  • The American Academy of Family Physicians recommends reducing warfarin dose by 50% when starting amiodarone, as it can significantly increase INR 3, 5
  • Digoxin dose should be reduced by 50% when starting amiodarone, according to the American Academy of Family Physicians 3, 5
  • The American Heart Association recommends caution when using amiodarone with statins, as it can increase the risk of myopathy/rhabdomyolysis 5, 8

Monitoring Requirements

  • The American Academy of Family Physicians recommends baseline assessment before starting amiodarone, including complete history and physical examination, chest radiograph, thyroid studies, liver transaminase levels, pulmonary function tests, and ophthalmologic examination 3, 4
  • Regular monitoring during treatment should include thyroid studies, liver transaminase levels, chest radiograph, and heart rate surveillance, as recommended by the American Academy of Family Physicians 3, 9

Important Clinical Considerations

  • Intravenous administration of amiodarone requires special precautions, including continuous electrocardiographic monitoring, as recommended by the American Academy of Pediatrics and the American Academy of Family Physicians 2, 3
  • The American Academy of Family Physicians and the American Heart Association recommend caution when using amiodarone due to its extensive drug interactions 3, 5, 8

Amiodarone Use in Hemodialysis Patients

Introduction to Amiodarone in Hemodialysis

  • Amiodarone is not contraindicated in patients undergoing hemodialysis, but requires careful monitoring due to potential complications, as recommended by the American Heart Association 10
  • Amiodarone is one of the few antiarrhythmic drugs that does not require dose adjustment in patients with chronic kidney disease (CKD) or those receiving dialysis, according to the American College of Cardiology 10

Monitoring and Treatment

  • Baseline assessment before starting amiodarone should include a chest radiograph and pulmonary function tests, as suggested by the American Academy of Family Physicians 11
  • Regular monitoring during treatment should include chest radiograph, as recommended by the American Academy of Family Physicians 11
  • When initiating amiodarone in hemodialysis patients, start with standard loading doses (typically 600-800 mg daily in divided doses until 10g total) and maintenance doses similar to non-dialysis patients (typically 200-400 mg daily), as advised by the American Academy of Family Physicians 11
  • Amiodarone is often considered after other options have been exhausted for patients with atrial fibrillation requiring rhythm control who are on hemodialysis, as recommended by the American Heart Association 12
  • It should be reserved for patients who are not candidates for catheter ablation and in whom other antiarrhythmics are ineffective or contraindicated, according to the American Heart Association 12

Amiodarone Contraindications and Precautions

Cardiovascular Considerations

  • The American College of Cardiology recommends caution in patients with bradycardia (heart rate less than 60 bpm), hypotension (systolic blood pressure less than 100 mmHg), and moderate or severe left ventricular failure 13
  • The American College of Cardiology also recommends caution in patients with severe chronic obstructive pulmonary disease, history of asthma, and severe peripheral vascular disease 13
  • Insulin-dependent diabetes is a precaution for amiodarone use, as recommended by the American College of Cardiology 13

Monitoring and Safety

  • The American Academy of Family Physicians recommends baseline assessment before starting amiodarone, including chest radiograph, thyroid studies, liver transaminase levels, and ophthalmologic examination (if preexisting visual impairment) 14
  • Regular monitoring during treatment should include thyroid studies, liver transaminase levels, and heart rate surveillance, especially during the first week of treatment, as recommended by the American Academy of Family Physicians 14
  • The American Academy of Family Physicians notes that intravenous amiodarone can cause heart block or bradycardia in 4.9% of patients and hypotension in 16% of patients 14
  • Discontinue amiodarone if liver enzyme levels are three times higher than normal, unless the patient is at high risk for recurrence of life-threatening arrhythmia, as recommended by the American Academy of Family Physicians 14
  • Pulmonary toxicity is the most serious potential adverse effect, presenting as subacute cough and progressive dyspnea, according to the American Academy of Family Physicians 14
  • Neurologic toxicity including ataxia, paresthesias, and tremor can occur and are often dose-related, as noted by the American Academy of Family Physicians 14

Amiodarone Use in Patients with Prolonged QT Interval

Safety Profile of Amiodarone with Prolonged QT

  • Amiodarone often causes marked QT interval prolongation; however, it has a low frequency of torsades de pointes compared to other antiarrhythmic agents 15
  • The risk of drug-induced torsade de pointes is lower with amiodarone than with "pure" potassium channel blockers, possibly due to its multiple ion channel inhibition mechanism 16

Risk Assessment and Monitoring

  • Patients should be monitored for QT prolongation during amiodarone therapy with baseline ECG documentation before initiation 15
  • QTc interval should be documented in the patient's medical record before the drug is initiated and thereafter at least every 8 hours 15
  • Careful monitoring for QT prolongation and abnormal TU waves is mandatory during amiodarone therapy 16
  • In patients reaching a QT interval >500 ms, dose reduction or discontinuation should be considered 16

Risk Factors That Increase Concern with Amiodarone Use

  • Women, patients with marked LV hypertrophy, severe bradycardia, ventricular arrhythmias, renal dysfunction, or hypokalemia/hypomagnesemia are at increased risk of proarrhythmia 16
  • Electrolyte abnormalities (especially hypokalemia or hypomagnesemia) significantly increase the risk of torsades de pointes and should be corrected before and during amiodarone therapy 15
  • Patients with slow heart rate, heart disease (especially left ventricular hypertrophy, ischemia, or low left ventricular ejection fraction) have higher risk 15

Specific Recommendations for Clinical Practice

  • When using amiodarone in patients with prolonged QT, measure QT in the same lead over time for consistency 15
  • If QT-related arrhythmias develop (sudden bradycardia, long pauses, enhanced U waves, T wave alternans, polymorphic ventricular premature beats), consider discontinuing amiodarone 15
  • For patients who develop a prolonged QTc >0.50 second with concerning features, the drug should be discontinued and ECG monitoring should continue until QTc decreases 15
  • Amiodarone can be safely administered in patients with structural heart disease, including heart failure, unlike many other antiarrhythmic agents 16

Special Considerations

  • Patients with new-onset bradyarrhythmias, severe hypokalemia or hypomagnesemia require particularly close monitoring if amiodarone is used 15

Amiodarone Contraindications and Precautions

Cardiovascular Considerations

  • The American Heart Association recommends that intravenous amiodarone should not be administered to patients with pre-excitation syndromes with atrial fibrillation, as it may increase ventricular response and potentially result in ventricular fibrillation 17
  • AV nodal ablation with permanent ventricular pacing should not be performed to improve rate control without prior attempts to achieve rate control with medications, according to the American Heart Association 17
  • Dronedarone should not be used to control ventricular rate in patients with permanent atrial fibrillation, as it increases the risk of stroke, myocardial infarction, systemic embolism, and cardiovascular death, as stated by the American Heart Association 17

Pulmonary Considerations

  • The American Academy of Family Physicians notes that pre-existing pulmonary disease increases the risk of pulmonary toxicity, which is the most serious potential adverse effect of amiodarone 18

Special Populations

  • The American Heart Association recommends that amiodarone should be avoided in pregnancy, especially in the first trimester, due to the risk of congenital malformations 19
  • Patients with risk factors for thyrotoxicosis, including female sex, cyanotic heart disease, low body mass index, and prior Fontan procedure, should be carefully monitored when taking amiodarone, as stated by the American Heart Association 19

REFERENCES

← Return to Home